1. Home
  2. NRSN vs FEMY Comparison

NRSN vs FEMY Comparison

Compare NRSN & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRSN
  • FEMY
  • Stock Information
  • Founded
  • NRSN 2017
  • FEMY 2004
  • Country
  • NRSN Israel
  • FEMY United States
  • Employees
  • NRSN N/A
  • FEMY N/A
  • Industry
  • NRSN Biotechnology: Pharmaceutical Preparations
  • FEMY Medical/Dental Instruments
  • Sector
  • NRSN Health Care
  • FEMY Health Care
  • Exchange
  • NRSN Nasdaq
  • FEMY Nasdaq
  • Market Cap
  • NRSN 29.8M
  • FEMY 30.2M
  • IPO Year
  • NRSN 2021
  • FEMY 2021
  • Fundamental
  • Price
  • NRSN $0.98
  • FEMY $0.88
  • Analyst Decision
  • NRSN Buy
  • FEMY Strong Buy
  • Analyst Count
  • NRSN 2
  • FEMY 2
  • Target Price
  • NRSN $14.00
  • FEMY $7.00
  • AVG Volume (30 Days)
  • NRSN 202.0K
  • FEMY 10.3M
  • Earning Date
  • NRSN 12-17-2025
  • FEMY 11-14-2025
  • Dividend Yield
  • NRSN N/A
  • FEMY N/A
  • EPS Growth
  • NRSN N/A
  • FEMY N/A
  • EPS
  • NRSN N/A
  • FEMY N/A
  • Revenue
  • NRSN N/A
  • FEMY $1,887,016.00
  • Revenue This Year
  • NRSN N/A
  • FEMY $81.63
  • Revenue Next Year
  • NRSN N/A
  • FEMY $158.53
  • P/E Ratio
  • NRSN N/A
  • FEMY N/A
  • Revenue Growth
  • NRSN N/A
  • FEMY 98.61
  • 52 Week Low
  • NRSN $0.80
  • FEMY $0.31
  • 52 Week High
  • NRSN $2.60
  • FEMY $1.80
  • Technical
  • Relative Strength Index (RSI)
  • NRSN 37.32
  • FEMY 58.07
  • Support Level
  • NRSN $0.89
  • FEMY $0.61
  • Resistance Level
  • NRSN $0.97
  • FEMY $0.88
  • Average True Range (ATR)
  • NRSN 0.07
  • FEMY 0.15
  • MACD
  • NRSN -0.01
  • FEMY 0.01
  • Stochastic Oscillator
  • NRSN 26.22
  • FEMY 54.73

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: